- Home
- FORA vs DTIL Comparison
FORA vs DTIL Comparison
Compare FORA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- DTIL
- Stock Information
- Founded
- FORA 2014
- DTIL 2006
- Country
- FORA United States
- DTIL United States
- Employees
- FORA N/A
- DTIL N/A
- Industry
- FORA Computer Software: Prepackaged Software
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- DTIL Health Care
- Exchange
- FORA Nasdaq
- DTIL Nasdaq
- Market Cap
- FORA 69.4M
- DTIL 81.4M
- IPO Year
- FORA N/A
- DTIL 2019
- Fundamental
- Price
- FORA $2.11
- DTIL $4.93
- Analyst Decision
- FORA
- DTIL Strong Buy
- Analyst Count
- FORA 0
- DTIL 2
- Target Price
- FORA N/A
- DTIL $47.00
- AVG Volume (30 Days)
- FORA 39.0K
- DTIL 258.8K
- Earning Date
- FORA 11-14-2025
- DTIL 11-03-2025
- Dividend Yield
- FORA N/A
- DTIL N/A
- EPS Growth
- FORA N/A
- DTIL N/A
- EPS
- FORA N/A
- DTIL N/A
- Revenue
- FORA $28,106,911.00
- DTIL $698,000.00
- Revenue This Year
- FORA $47.82
- DTIL N/A
- Revenue Next Year
- FORA $10.11
- DTIL $135.19
- P/E Ratio
- FORA N/A
- DTIL N/A
- Revenue Growth
- FORA 37.47
- DTIL N/A
- 52 Week Low
- FORA $1.64
- DTIL $3.61
- 52 Week High
- FORA $4.03
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- FORA 44.32
- DTIL 32.38
- Support Level
- FORA $2.05
- DTIL $4.68
- Resistance Level
- FORA $2.30
- DTIL $5.41
- Average True Range (ATR)
- FORA 0.10
- DTIL 0.57
- MACD
- FORA -0.01
- DTIL -0.26
- Stochastic Oscillator
- FORA 28.78
- DTIL 8.17
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.